India's pharmaceutical industry is gaining its position as a global leader. The pharma market in India is expected to touch US$ 74 billion in sales by 2020 from the current US$ 11 billion, according to a PricewaterhouseCooper (PwC) report.
India has world renowned capacity in producing low cost, high quality bulk and generic drugs. The share of Indian pharma companies in the total pie of approvals for generic drugs (called abbreviated new drug applications (ANDA) approvals in the US) has risen steadily. In 2011 itself, more than a third of the ANDA approvals were by Indian firms. As a consequence, formulation exports from India, essentially generic drugs, have grown at 21 per cent compounded annual growth rate (CAGR) between 2005-06 and 2010-11. With patents of about US$ 150 billion worth of drugs set to expire between 2010 and 2015, it is expected that the growth momentum in exports would continue over the next five years, with exports growing at 14-16 per cent CAGR, as per Crisil Research.
According to a recent trend, multinational drug companies are showing a healthy growth in the Indian market. Out of 25 top medicine brands by sales last year, 13 were global drug major such as Pfizer, GSK and Novartis. A recent report of market research entity AIOCD AWACS reveals that brand-building exercise is fast becoming more evident in a predominantly generic Indian medicine market.
Ranbaxy gets US FDA nod for acne treatment drug
The Hindu Business Line: May 28, 2012
Ranbaxy Laboratories Ltd on Monday got approval from the US Food and Drug Administration to launch Absorica in the US market. "Absorica is a milestone in our commitment to serve the dermatology community and will be the flagship brand for Ranbaxy's specialised dermatology sales force," Mr Venkat Krishnan, Senior Vice President and Regional Director, Americas, Ranbaxy said in a company statement.
Dr Reddy's launches Lansoprazole capsules in US
The Hindu Business Line: May 21, 2012
Pharma major Dr Reddy's Laboratories has launched over-the-counter Lansoprazole delayed-release capsules in the US market. The Hyderabad-based company will market the product under store brand labels in the US market.
Aurobindo gets USFDA nod for anti-HIV drugs
The Hindu Business Line: May 18, 2012
Aurobindo Pharma Ltd has received final approval from the US Food and Drug Administration to manufacture and market Lamivudine and Zidovudine tablets. The tablets are the generic equivalent of ViiV Healthcare Company's Combivir tablets and are indicated for the treatment of Human Immunodeficiency Virus (HIV) infected adults and children.
Indian pharma companies like Hetero, Alembic, Lupin, Dr Reddy's dominating US generic space
The Economic Times: May 04, 2012
India is playing a dominant role in the US generic pharma space, having cornered over half the certified dossiers filed globally for active pharmaceutical ingredients (API). Drug companies from India filed 51% of the overall global applications, also called drug master filings (DMF), in the US market during calendar year 2011. DMFs are essentially approvals to supply complex raw materials to all generic manufacturers servicing the US market, which is the most lucrative of all global markets.